Showing posts with label if I had... Show all posts
Showing posts with label if I had... Show all posts

Friday, March 4, 2011

If I Had - Pre-diabetes/video

Welcome to Insidermedicine's If I Had; where we get a chance to ask an expert what they would do if they had a particular medical condition

If I Had - Pre-diabetes -

Dr. Venkat Narayan, MD, MSc, MBA, Rollins School of Public Health, Emory University

What is diabetes?
Diabetes, essentially is a metabolic condition which is characterized by high levels of glucose, so for example if you had your glucose measured when you were fasting and it was greater than 126mg/dl, you have diabetes. Another way of diagnosing diabetes is to have what’s called a glucose tolerance test, in which you are given a volume of glucose to drink and a measurement is taken after 2 hours, and if the measurement is greater than 200mg/dl, that is also considered to be diabetes. Essentially diabetes is a metabolic condition which also has abnormalities in blood pressure, lipids, et cetera, it is not just glucose.


Pre-diabetes is a condition which puts a person at high risk of diabetes; your fasting glucose of between 100 and 125mg/dl, and your two hour glucose of between 140 and 200mg/dl. Again, you don’t have diabetes, but you’re at high risk of developing diabetes. The pre-diabetic group is a group where we target prevention.

What diagnositc tests are available?
Essentially the policy today is if you are at high risk of developing diabetes, when you go to your doctor for a regular checkup, you should get your glucose checked, ideally a fasting glucose test would be the easiest thing to do since it is just one blood draw, and if that is high they can repeat it to confirm it. There are other tests (eg capillary glucose) but they are not as good as the fasting glucose test.

How can diabetes be treated and prevented?
Preventing diabetes in people with pre-diabetes is quite different from treating people who already have diabetes. If somebody is at high risk, they should go to their doctor and have a blood glucose done, and if they are found to have pre-diabetes, what we recommend as the primary treatment would be an aggressive lifestyle intervention; there is solid evidence to support this. Essentially what we mean is getting a person to, firstly, do about 30 minutes of physical activity per day (this can be brisk walking), secondly, to try and lose weight, about 5-7% of their weight if they are overweight (eg a 200lb person would lose between 10-14lbs of weight), and thirdly, to modify their diet by lowering both portion size, lowering amount of fat in the diet, and also increasing the fiber in the diet. This would be the initial strategy and it is often helped by having counselors and social support groups to help achieve these goals, and by monitoring progress. In selected people who, for example, have very high levels of fasting glucose, and also have high levels of 2-hour glucose, there may be a role for adding the drug Metformin, but I would like to emphasize that the primary way of preventing diabetes is lifestyle modification, and it has huge benefits in preventing progression to diabetes by about 50% or higher.

Once a person is diagnosed to have diabetes, which is a 2-hour glucose of 200mg/dl or over, or a fasting glucose of 126mg/dl and over, then it is a different situation, and the current recommendation is to again start on lifestyle intervention, but the person may require Metformin, and beyond that blood glucose control may need to be tailored to the individual; at some point they may need another drug, or at some point in life they may need insulin. We manage that based on glucose levels. But it also presents the opportunity of managing other risk factors for cardiovascular disease which is a major cause of morbidity and death among people with diabetes. A person with diabetes would need to attend to their glucose levels but also for blood pressure control, controlling their lipids, which is high cholesterol levels, taking Aspirin which can prevent a lot of vascular complications, and there may be a role for regularly examining the eyes to prevent these complications from arising.

If I had pre-diabetes…
If I had pre-diabetes, given the knowledge we have about the condition, I would be very optimistic about preventing diabetes. Clearly, evidence suggests that if I could change my lifestyle, do simple things like 30 minutes of physical activity per day, modify my diet, and try and lose between 5 & 7% of my body weight, then I can prevent going on to get diabetes by 50%, which is a major gain. This is achievable. Lifestyle intervention is far more effective than any drug in the field, and we’ve also found from studies that even if you have genes for diabetes, lifestyle intervention can eliminate your risk very substantially, so it is something that I would take very seriously. So if I had pre-diabetes, I would very aggressively embark on lifestyle intervention, I would seek any help available to achieve that and I would also be in regular contact with my physician at least once every two or three years to make sure that I am not progressing toward diabetes.


Prediabetes FAQs

Q: What is prediabetes and how is it different from diabetes?
A: prediabetes is the state that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of diabetes. About 11 percent of people with prediabetes in the Diabetes Prevention Program standard or control group developed type 2 diabetes each year during the average 3 years of follow-up. Other studies show that many people with prediabetes develop type 2 diabetes in 10 years.

Q: Is prediabetes the same as Impaired Glucose Tolerance or Impaired Fasting Glucose?
A: Yes. Doctors sometimes refer to this state of elevated blood glucose levels as Impaired Glucose Tolerance or Impaired Fasting Glucose (IGT/IFG), depending on which test was used to detect it.

Q: Why do we need to give it a new name? Has the condition changed?
A: The condition has not changed, but what we know about it has. We are giving IGT/IFG a new name for several reasons. prediabetes is a clearer way of explaining what it means to have higher than normal blood glucose levels. It means you are likely to develop diabetes and may already be experiencing the adverse health effects of this serious condition. People with prediabetes are at higher risk of cardiovascular disease. People with prediabetes have a 1.5-fold risk of cardiovascular disease compared to people with normal blood glucose. People with diabetes have a 2- to 4-fold increased risk of cardiovascular disease. We now know that people with prediabetes can delay or prevent the onset of type 2 diabetes through lifestyle changes.

Q: How do I know if I have prediabetes?
A: Doctors can use either the fasting plasma glucose test (FPG) or the oral glucose tolerance test (OGTT) to detect prediabetes. Both require a person to fast overnight. In the FPG test, a person's blood glucose is measured first thing in the morning before eating. In the OGTT, a person's blood glucose is checked after fasting and again 2 hours after drinking a glucose-rich drink.

Q: How does the FPG test define diabetes and prediabetes?
A: Normal fasting blood glucose is below 100 mg/dl. A person with prediabetes has a fasting blood glucose level between 100 and 125 mg/dl. If the blood glucose level rises to 126 mg/dl or above, a person has diabetes.

Q: How does the OGTT define diabetes and prediabetes?
A: In the OGTT, a person's blood glucose is measured after a fast and 2 hours after drinking a glucose-rich beverage. Normal blood glucose is below 140 mg/dl 2 hours after the drink. In prediabetes, the 2-hour blood glucose is 140 to 199 mg/dl. If the 2-hour blood glucose rises to 200 mg/dl or above, a person has diabetes.

Q: Which test is better?
A: According to the expert panel, either test is appropriate to identify prediabetes.

Q: Why do I need to know if I have prediabetes?
A: If you have prediabetes, you can and should do something about it. Studies have shown that people with prediabetes can prevent or delay the development of type 2 diabetes by up to 58 percent through changes to their lifestyle that include modest weight loss and regular exercise. The expert panel recommends that people with prediabetes reduce their weight by 5-10 percent and participate in some type of modest physical activity for 30 minutes daily. For some people with prediabetes, intervening early can actually turn back the clock and return elevated blood glucose levels to the normal range.

Q: Will my insurance cover testing and treatment?
A: Because all insurance plans are different, this is a difficult question to answer. However, Medicare and most insurance plans cover diabetes testing for people suspected of having diabetes. People at risk for diabetes are also at risk for prediabetes. Since the test is the same and the risk factors are the same for both conditions, a prediabetes test may be covered. It is best to consult your physician and health insurance representative with specific coverage questions.

Q: What is the treatment for prediabetes?
A: Treatment consists of losing a modest amount of weight (5-10 percent of total body weight) through diet and moderate exercise, such as walking, 30 minutes a day, 5 days a week. Don't worry if you can't get to your ideal body weight. A loss of just 10 to 15 pounds can make a huge difference. If you have prediabetes, you are at a 50 percent increased risk for heart disease or stroke, so your doctor may wish to treat or counsel you about cardiovascular risk factors, such as tobacco use, high blood pressure, and high cholesterol.

Q: Who should get tested for prediabetes?
A: If you are overweight and age 45 or older, you should be checked for prediabetes during your next routine medical office visit. If your weight is normal and you're over age 45, you should ask your doctor during a routine office visit if testing is appropriate. For adults younger than 45 and overweight, your doctor may recommend testing if you have any other risk factors for diabetes or prediabetes. These include high blood pressure, low HDL cholesterol and high triglycerides, a family history of diabetes, a history of gestational diabetes or giving birth to a baby weighing more than 9 pounds, or belonging to an ethnic or minority group at high risk for diabetes.

Q: How often should I be tested?
A: If your blood glucose levels are in the normal range, it is reasonable to be checked every 3 years. If you have prediabetes, you should be checked for type 2 diabetes every 1-2 years after your diagnosis.

Q: Could I have prediabetes and not know it?
A: Absolutely. People with prediabetes don't often have symptoms. In fact, millions of people have diabetes and don't know it because symptoms develop so gradually, people often don't recognize them. Some people have no symptoms at all. Symptoms of diabetes include unusual thirst, a frequent desire to urinate, blurred vision, or a feeling of being tired most of the time for no apparent reason.

Q: Should children be screened for prediabetes?
A: We are not recommending screening children for prediabetes because we don't have enough evidence that type 2 diabetes can be prevented or delayed in children at high risk for the disease. However, a study published in the March 14, 2002, issue of the New England Journal of Medicine found 25 percent of very obese children and 21 percent of very obese adolescents had prediabetes. If future studies show that early intervention also works for children, a recommendation could be forthcoming.

http://www.diabetes.org/diabetes-basics/prevention/pre-diabetes/pre-diabetes-faqs.html

Friday, February 18, 2011

Friday Video; If I Had Dry Eyes....

Friday If I Had.......
Once a week the blog will post a video from Insidermedicine's series deemed "If I Had." These videos cover numerous disorders and diseases.
.
,Sjogren's Syndrome (SS), an autoimmune disease characterized by dry eyes and dry mouth has been found in some studies to be more common in HCV infected patients. They differ from primary SS in that they do not have lung and kidney involvment

Todays Topic
.
If I Had; Dry Eye -
.
Dr. Reza Dana, MD, MSc, MPH, Massachusetts Eye & Ear Infirmary and Harvard Medical School


.

Evaluation of ocular surface damage and dry eye status in chronic hepatitis C at different stages of hepatic fibrosis.


Gumus K, Yurci A, Mirza E, Arda H, Oner A, Topaktas D, Karakucuk S.
Department of Ophthalmology, Division of Gastroenterology, Erciyes University School of Medicine, Kayseri 38039, Turkey. drkorayg@hotmail.com 2009

Abstract
PURPOSE: The purpose of this study was to explore changes in ocular surface and tear function parameters in chronic hepatitis C at different stages of hepatic fibrosis.

METHODS: Fifty-four patients with biopsy-proven chronic hepatitis C and 54 age- and sex-matched healthy control subjects without systemic hepatitis C infection were examined with the Ocular Surface Disease Index questionnaire, Schirmer with and without anesthesia, tear film breakup time, and scoring of ocular surface Lissamine green staining using modified Oxford and van Bijsterveld scoring systems and corneal fluorescein staining.

RESULTS: Patients with chronic hepatitis C scored significantly worse than the control subjects on all parameters: modified Oxford scores of Lissamine green staining (5.5/3.0; P less then 0.001), Oxford and van Bijsterveld scores (4.0/2.0; P less then 0.001), and corneal fluorescein staining (1.5/0.0; P = 0.001).

The chronic hepatitis C group also had higher Ocular Surface Disease Index scores than the control subjects (22.3/13.7; P = 0.001). Schirmer with and without anesthesia and tear film breakup time scores were found to be lower in patients with chronic hepatitis C (P less then 0.001). Moreover, patients with advanced stages of hepatic fibrosis (stages 4-6) had significantly lower values of tear film breakup time and worse Ocular Surface Disease Index scores and ocular surface vital dye staining than those with initial stages of hepatic fibrosis (stages 0-3).


CONCLUSION: Patients with chronic hepatitis C, especially those with advanced stages of hepatic fibrosis, were more likely to exhibit severe ocular surface damage and signs of dry eye.
PMID: 19724213 [PubMed - indexed for MEDLINE]

Friday, February 11, 2011

Fridays "If I Had" Video:Blood in my Stool

Friday If I Had.......
Once a week the blog will post a video from Insidermedicine's series deemed "If I Had." These videos cover numerous disorders and diseases.
,

Todays Topic
If I Had; Blood in my Stool - Dr. Jeffrey Meyerhardt, MD, MPH
.
.

.

From; Insidermedicine's

If I Had, is a video series where we get a chance to ask an
expert what they would do if they had a medical condition.

See Other If I Had Videos......

Also On The Blog; What Is a Healthy Stool ?

,

,

Friday, February 4, 2011

Friday If I Had..A Solid Organ Transplant and Was Concerned About Skin Cancer

Friday If I Had.......
Once a week the blog will post a video in a series deemed "If I Had."
These videos cover numerous disorders and diseases.
,
If I Had, is a video series where we get a chance to ask an expert what they would do if they had a medical condition.
.
Todays Topic
If I Had ; A Solid Organ Transplant and Was Concerned About Skin Cancer -
/
Dr. Thomas Stasko, MD, Vanderbilt University Medical Center
..


.
Immunosuppression

Immunosuppression also contributes to the formation of nonmelanoma skin cancers. Among solid-organ transplant recipients, the risk of SCC is 65 to 250 times higher, and the risk of BCC is 10 times higher than that observed in the general population.[36-38]
Nonmelanoma skin cancers in high-risk patients (solid-organ transplant recipients and chronic lymphocytic leukemia patients) occur at a younger age, are more common and more aggressive, and have a higher risk of recurrence and metastatic spread when compared to these cancers in the general population.[39,40] Among patients with an intact immune system, BCCs outnumber SCCs by a 4:1 ratio; in transplant patients, SCCs outnumber BCCs by a 2:1 ratio.

This increased risk has been linked to an interaction between the level of immunosuppression and UV radiation exposure.
As the duration and dosage of immunosuppressive agents increase, so does the risk of cutaneous malignancy; this effect is reversed with decreasing the dosage of, or taking a break from, immunosuppressive agents.
Heart transplant recipients, requiring the highest rates of immunosuppression, are at much higher risk of cutaneous malignancy than liver transplant recipients, in whom much lower levels of immunosuppression are needed to avoid rejection.
[36,41] The risk appears to be highest in geographic areas with high UV exposure. When comparing Australian and Dutch organ transplant populations, the Australian patients carried a fourfold increased risk of developing SCC and a fivefold increased risk of developing BCC.[42] This finding underlines the importance of rigorous sun avoidance, particularly among high-risk immunosuppressed individuals.

Certain immunosuppressive agents have been associated with increased risk for SCC. Kidney transplant patients who received cyclosporine in addition to azathioprine and prednisolone had a 2.8-fold increase in risk of SCC over those kidney transplant patients on azathioprine and prednisolone alone.[36] In cardiac transplant patients, increased incidence of SCC was seen in individuals who had received OKT3 (muromonab-CD3), a murine monoclonal antibody against the CD3 receptor.[43]
.
Squamous Cell Carcinoma
,

Friday, January 28, 2011

Friday" If I Had..." /Video:Non-Hodgkin's lymphoma

Friday If I Had.......
Once a week the blog will post a video in a series deemed "If I Had."
These videos cover numerous disorders and diseases.
Physicians share what they would do "IF they Had..." the disease in the topic video.

Today the topic is:
If I Had Night Sweats And An Enlarged Painless Lymph Node In My Neck -
l
Studies have shown that patients with hepatitis C have a 20% to 30% increased risk of developing non-Hodgkin's lymphoma and a 3-fold higher risk of developing Waldenstrom's macroglobulinemia, a low-grade lymphoma.
,.
.
,
.
.
Dr. Jonathan W. Friedberg, M.D, University of Rochester Medical Center
At the American Society of Hematology meeting in San Francisco, we spoke with Dr. Jonathan Friedberg, who is Associate Professor and Chief, Department of Medicine at the University of Rochester School of Medicine. Dr. Friedberg is also Associate Professor at the James P. Wilmot Cancer Center.
;
;
How many stages are there in non-Hodgkin's lymphoma?
Every weekday, a CNNHealth expert doctor answers a viewer question.
On Wednesdays, it's Dr. Otis Brawley, chief medical officer at theAmerican Cancer Society.
Question asked by Paula Holman-Yorba of San Bernardino, California

How many stages are there in non-Hodgkin's lymphoma?
.
Expert answer
Two weeks ago, Paula asked about staging of non-Hodgkin's lymphoma.
We discussed cancer staging in general.
This week, we discuss lymphoma and its staging and prognosis.
Lymphoma is cancer of the lymphatic system, which is an important part of the immune system. The lymphatic system consists of conduits or tubes throughout the body with filters called lymph nodes along the path. The system carries a clear fluid with immune fighting cells such as lymphocytes.

Lymphoma is a disease that is increasing in incidence in the Western world. Common risk factors include exposure to:

• ionizing radiation;
• certain chemicals such as benzene, insecticides, or herbicides; and
• some viruses such as HIV, HTLV 1 and 2.

There is also evidence that people with immune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE, or lupus), or celiac sprue are at higher risk of developing lymphoma. Patients with immune hyperstimulation from H. pylori infection of the stomach or hepatitis C are also at increased risk of certain types of lymphoma.

The appropriate treatment and the prognosis for a lymphoma patient are related to a combination of the type of lymphoma and stage of disease. The type of tumor is determined by a pathologist's microscopic examination of a biopsy of the tumor.

There are two major types of lymphoma: the Hodgkin's lymphomas and the non-Hodgkins lymphomas. HL spreads primarily through the ducts of the lymph system. NHL spreads more through blood vessels. There are five subtypes of HD and more than two dozen types of NHL.
These NHL are categorized into three groups: the indolent, intermediate and aggressive.
The stage or degree of spread of the disease is determined by the physical examination and radiologic imaging. A TNM stage, discussed last week, is determined and usually translated into what is known as the Ann Arbor staging system with Cotswolds modifications.
This is the overall or summary stage, in brief:

• Stage I - Lymphoma involving a single lymph node region (I) or a single node and the organ next to it.

• Stage II - Involvement of two or more lymph node regions in the chest or two or more in the abdomen or the area of the retroperitoneum (low back). There can be direct extension of lymphoma from the lymph node chain into an adjacent organ.

• Stage III - Involvement of lymph node in the abdomen and the chest or the retroperitoneum and the chest. Involvement of the spleen, which is located in the left upper abdomen, is stage III disease.

• Stage IV - Diffuse or disseminated lymphoma involving one or more organs or tissues without associated lymphatic involvement.

Patients with stage I or stage II disease are then further stratified for treatment purposes into favorable and unfavorable prognosis disease, based upon the presence or absence of certain clinical features, such as age and B symptoms (weight loss, fevers, night sweats, and large volume of disease in the chest).

Laboratory studies are done to determine the type of cancerous cells. There are drugs specific to the treatment of what are known as B cell lymphomas. B cell positive versus T cell positive or other laboratory markers can also be used to predict patterns of spread and patterns of invasion of a lymphoma.

The appropriate treatment of a lymphoma varies by the type of tumor and by the stage. Stage I and II lymphomas can often be treated with radiation alone. They are of limited size and spread, such that they can be illuminated by one radiation beam. Stage III and IV lymphomas generally must be treated with a series of chemotherapy drugs active in lymphoma. Type of tumor is very important, as indolent lymphoma usually presents as widely spread or stage IV disease, but can often be appropriately watched, and treatment can sometimes be deferred for a decade or more. On the other hand, the aggressive lymphomas can be a medical emergency requiring immediate treatment.

The international prognostic index (IPI) is used to determine prognosis for patients with lymphoma. The index takes into account the the type of lymphoma, stage of disease, and what markers or genes are expressed in the tumor. As a whole, lymphoma is one of the most treatable of malignancies. While the prognosis for many of the lymphomas can be very good, there are some lymphomas that are very difficult to treat.
Ask experts a question
.
.
Hepatitis C may play a role in ocular adnexal non-Hodgkin lymphoma
.
Arch Ophthalmol.
Posted on October 25, 2010
2010;128(10):1295-1299.
.
The prevalence of hepatitis C infection may be relevant to ocular adnexal non-Hodgkin lymphoma, and hepatitis C may influence the initial appearance of the disease, a study said.
In the retrospective comparative study, medical records of 129 patients with ocular adnexal non-Hodgkin lymphoma were reviewed.
The prevalence of hepatitis C virus (HCV) infection among the patients was 17.8%, and seropositivity for infection was significantly associated with extraorbital lymphoma at the onset, the study said.
.
A high prevalence of mucosa-associated lymphoid tissue disease (79.8%) was also noted.
Ninety-nine patients who underwent radiotherapy and chemotherapy achieved complete remission, while 23.6% of patients with HCV-seronegative status and 21.7% of patients with HCV-seropositive status relapsed.
"However, the overall and disease-free survival of the infected patients are not statistically different than that of patients who are not infected," the authors said.

Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis

Author: Geri, G., Terrier, B., Semoun, O., Saadoun, D., Sene, D., Charlotte, F., Merle-Beral, H., Musset, L., Resche-Rigon, M., Cacoub, P.Publication: Annals of the Rheumatic DiseasesVolume: 69, Issue: 12, Pages: 2177 to 2180
Date: Saturday, November 20, 2010
.
Objective
To evaluate clinical and biological surrogate markers associated with the presence of B cell non-Hodgkin's lymphoma= (B-NHL) in patients with hepatitis C virus (HCV) with mixed cryoglobulinaemia (MC) vasculitis.
.
Methods
A total of 104 patients with HCV-MC vasculitis (including 20 with B-NHL) were included. The main clinical and biological markers associated with the presence of B-NHL were evaluated.
.
Results
Patients with B-NHL compared to those without showed higher rates of poor general status (40% vs 16.7%; p=0.032), purpura (90% vs 66.7%; p=0.05), renal (50% vs 28.6%; p=0.11) and cardiac involvement (15% vs 0%; p=0.0006), higher cryoglobulin levels (1.44 g/litre vs 0.67 g/litre; p=0.0004), and lower C4 (0.025 g/litre vs 0.06 g/litre; p=0.001) and -globulin levels (5.3 g/litre vs 13.3 g/litre; p less then 0.0001). The free light chain / ratio was more frequently abnormal in patients with than without B-NHL (64.3% vs 33.3%, p=0.10). On multivariate analysis, only -globulin level was associated with the presence of B-NHL (OR 0.77 (95% CI –0.44 to –0.13), p=0.0006). The optimal cut-off value for -globulin level was 9 g/litre, with sensitivity, specificity, positive and negative predictive values for the presence of B-NHL of 75%, 82%, 50% and 93%, respectively
.
Conclusions
In patients with HCV-MC, a low -globulin level (less then 9 g/litre) is strongly associated with the presence of B-NHL.
FULL TEXT
.
.
Reuters) - People infected with hepatitis B virus are around twice as likely to develop non-Hodgkin lymphoma, reported on Aug 3, 2010 .

Hepatitis B was already known to cause liver cancer and some scientists had suspected it might cause lymphoma, too. The study, published in Lancet Oncology, confirms this.
.
Hepatitis C is also linked to lymphoma.

The blood cancer is not common and widespread vaccination against the viruses is unlikely to affect non-Hodgkin lymphoma rates much, the researchers noted. But it may be possible to treat the virus and help non-Hodgkin lymphoma patients, they said.
Dr. Eric Engels of the U.S. National Cancer Institute and Sun Ha Jee of Yonsei University in Seoul studied the records of more than 600,000 people in South Korea, where hepatitis B was extremely common before a vaccination campaign began in 1995.

Of these, 53,000 or about 9 percent had evidence of hepatitis B infection. After 14 years, rates of non-Hodgkin lymphoma were more common among the infected people -- 19.4 cases per 100,000 people compared to 12.3 per 100,000 who did not have hepatitis B.
Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation, according to the U.S. Centers for Disease Control and Prevention. The various hepatitis viruses are not closely related -- the word hepatitis means inflammation of the liver.
An estimated 350 million people worldwide are infected with hepatitis B virus, which causes 340,000 cases of liver cancer a year and kills between 500,000 and 1.2 million people a year.
Researchers think both hepatitis B and C may cause lymphoma by overstimulating the immune system as it tries to fight off the liver infection.
(Reporting by Maggie Fox, editing by Alan Elsner)
.

Friday, January 21, 2011

In The News: Hepatitis C Jan 21


An update today on the success of growing human liver cells; "Researchers suggest that this liver tissue could be used in place of donor organs during liver transplantation or during the bridge period until a suitable donor is available for patients with acute liver failure.".. Read more..

From India the news of an Ebola-like hemorrhagic fever has killed three people in western India. It was reported that a woman died after an insect-transmitted illness, as did the doctor and nurse who treated her... Read more....

A new record for organ transplants in BC
More living donors, more people signing up. More living donors and an increase in British Columbians signing donor cards have lead to a new record for organ transplants in 2010. Almost 300 procedures were done in the province last year.. Read More..
Andrea Macpherson Jan 21, 2011 10:21:07 AM
.
Recent highlights from the Ideas blog
.
By Joshua Rothman
January 23, 2011

Last week, Apple announced that Steve Jobs would be taking a medical leave. Jobs has struggled with his health since 2004, when he had surgery for pancreatic cancer; in 2009, he had a liver transplant. Among technology and business analysts, the talk is, prematurely, all about the fate of a post-Jobs Apple...Read More..


.
The Good News

Today Vertex's drug Telaprevir Received FDA Priority Review" both in U.S. and Canada. On Jan 6th Mercks Boceprevir received FDA Priority Review and EMA Accelerated Assessment. Telaprevir and boceprevir have been deemed the new generation of drugs both of which appear to be able to improve sustained response while shortening duration of therapy.
.
The Confusion

The headlines on these two drugs have been misleading and confusing for anyone newly diagnosed. With tag lines reading; "New Hepatitis C Drugs Telaprevir, and Boceprevir can boost cure rates as high as 75 percent with only 24 weeks of treatment". Okay, maybe I embellished a bit, but you get the gist of what I am trying to convey. If I were new to the world of hepatitis C my assumption would be I had a 75 percent chance at a cure. I may even assume treatment duration would be at 24 weeks. However, there are many factors to consider when figuring in these cure rates. Boceprevir and telaprevir will improve the chance for achieving a cure, but a 75 percent cure rate will not be seen in all people treating HCV. The cure rate for these drugs differ and hinge on genotype, treatment naïve patients, relapsers, partial responders, null responders, amount of liver damage/host factors, race and age. The lingo used by physicians or technicians can be difficult to remember; below is a clear definition of these terms. In this blog entry I hope to establish a better understanding in relation to achieving SVR/cure when treating with telaprevir or boceprevir.... Read More....

From Medical News Today

EHSI Forms Joint Venture To Develop Stem-Cell Treatment For Liver Disease
20 January 2011Emerging Healthcare Solutions, Inc. (PinkSheets: EHSI) announced that it has entered into a joint venture agreement with its wholly owned subsidiary, Celulas Genetica, in order to pursue testing of the revolutionary...Read more

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) have announced the beginning of a Phase 2 clinical trial testing the ability of a human...Read article
.

Biosimilars Update

This blog has covered biosimilars a handful of times. For those of you who have missed the updates biosimilars are copycat versions of expensive biotechnology drugs. Although technically these "biosimilars" are not called generics. Quoted from Reuters ;"Because of the complexity of biotech drugs, which are produced through biological processes that generally involve recombinant DNA technologies, they are often called "biosimilars" rather than generic copies. Biotech drugs are usually made from living cell lines controlled by different manufacturers, it is impossible for generic companies to make identical copies as they do with simple chemical-based drugs, which do not require fresh clinical trials. Biosimilars of drugs like Amgen's white blood cell-booster Neupogen are already on the market in Europe."

Today at pharmalot Mr. Ed Silverman reported the latest battle which involves; "a group of generic drugmakers, insurers and pharmacy benefit managers, which are pushing back against a recent effort by brand-name drugmakers to weaken a part of healthcare reform that is supposed to create competition for expensive biologics."

"The provision says generics can enter the market after a brand-name biologic has had exclusivity for 12 years."............ Read More.........
/
Friday If I Had.......
/
Once a week the blog will post a video in a series deemed "If I Had."
These videos cover numerous disorders and diseases.
Physicians share what they would do "IF they Had..." the disease in the topic video.
.
Today the topic is: If I Had leg swelling and pain…
.
Dr. Lawrence Hofmann, MD.
.
Chief of Interventional Radiology at Stanford Hospital & Clinics





From The One And Only Motley Fool


Mark your calendars, Fools: May is going to be a solid month for drug approvals.
The multiyear marathon between Schering-Plough and Vertex Pharmaceuticals (Nasdaq: VRTX) to develop the next-generation hepatitis C drug is finally coming to a close. Vertex announced yesterday that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. Not surprisingly, given the unmet need, the agency will give telaprevir a priority review, so Vertex should hear back on or before May 23.
Merck (NYSE: MRK), which took over development of boceprevir when it bought Schering-Plough, announced a few weeks ago that the FDA had accepted its application with a priority review, as well. Since one drug isn't all that material to Merck's business, the company didn't feel compelled to give an exact date of the submission, so we don't know exactly when the FDA will come back with a decision.

If you want to put it on your calendar, you'll need a highlighter to mark off the potential weeks that Merck could hear. If the FDA took the same amount of time to review the applications, and the two companies announced the acceptance the same amount of time after they heard from the agency -- two big ifs -- Merck's PDUFA date is May 9. Perhaps the drugmaker will give investors an exact PDUFA date on its fourth-quarter earnings call.
In the big picture, which company launches first in the U.S. or Europe -- where Merck will go up against Vertex's marketing partner Johnson & Johnson (NYSE: JNJ) -- doesn't really matter. A few weeks or even a difference of a month or two doesn't really matter compared with who has the better drug.

Vertex clearly has the advantage here. While the drugs haven't been compared head to head, telaprevir appears to work better in every patient population tested so far.
While I think telaprevir is a best-in-class drug, I'm hesitant to invest because everyone else seems to think the same thing. The drugmaker has a market cap of more than $8 billion. That's substantially larger than companies like Dendreon (Nasdaq: DNDN) and Onyx Pharmaceuticals (Nasdaq: ONXX), which already have drugs on the market. Sure, the hepatitis C market is largely untapped, but there's a heck of a lot of sales already baked into that $8 billion.


Off The Cuff


It isn't just dog trainers and the occasional finicky spouse who want you to keep your pets off the bed. A new report in the journal Emerging Infectious Diseases found that of the 250 known zoonotic diseases, which are transmitted between humans and animals, more than 100 are derived from domestic pets — yes, even from your precious Sparkles or Daisy....Read more


‘Give Me Your Heart’
By JOYCE CAROL OATES
Published: January 21, 2011

Excerpt From Book:

I’ve learned that you, the renowned Dr. K——, are one who has generously signed a “living will” donating his organs to those in need. Not for Dr. K—— an old-fashioned, selfish funeral and burial in a cemetery, nor even cremation. Good for you, Dr. K——! But I want only your heart, not your kidneys, liver, or eyes. These I will waive, that others more needy will benefit...
Related:Sunday Book Review: ‘Give Me Your Heart’ by Joyce Carol Oates (January 23, 2011)



,

Saturday, January 15, 2011

Hepatitis C : If I Had (Video) Floaters Disrupting My Vision

Once a week the blog will post a video in a series deemed "If I Had."

These videos cover numerous disorders and diseases.

Physicians share what they would do "IF they Had..." the disease in the topic video.

Today the topic is: If I Had - Retinal Detachment

One Symptom: Floaters

Dr. Jeff Gale, Assistant Professor in the Dept. of Ophthalmology at Queen's University, discusses what he would do he if had retinal detachment.

.

Visit Insider Medicine
http://www.insidermedicine.com/

Click on the tag " If I Had... For Additional Videos

.

Side effects of Pegasys and Copegus

Eye problems (blurred, loss of vision, and retinal detachment)

In 2009 the FDA issued a new class safety labeling updates for alpha interferon products.

Pegylated interferon alpha (Pegasys or PegIntron) is standard treatment for hepatitis C, and pegylated or conventional interferon are used for hepatitis B.

.

Included in the update was Serious retinal detachment.

Eye problems:

Changes in vision such as a decrease or loss of vision (blindness) may happen in some patients. You should have an eye exam before you take [alpha interferon products]. If you have eye problems or have had them in the past you may need eye exams while you are taking [alpha interferon products]. Tell your healthcare provider or eye doctor right away if you have any changes in your vision while taking [alpha interferon products].

9/04/09

Source

R Klein and K Struble (Food and Drug Administration). New class safety labeling updates for alpha interferon products. FDA Hepatitis Update.

September 1, 2009.

Click Here For Complete Update

Friday, January 7, 2011

Hepatitis C Morning News: 01-07





Vertex Ends Clinical Trial of Dual Telaprevir plus VX-222 Regimen SUMMARY: Vertex Pharmaceuticals announced last month that it is discontinuing a clinical trial arm that was testing a 2-drug regimen of the hepatitis C virus (HCV) protease inhibitor telaprevir plus the HCV polymerase inhibitor VX-222, after preliminary results showed that people taking the dual combination were more likely to experience viral breakthrough. The company will continue to test telaprevir plus VX-222 in combination with pegyalted interferon/ribavirin and ribavirin alone.



No Tenofovir Resistance after 3 Years among Chronic Hepatitis B Patients SUMMARY: Tenofovir (Viread) remains active against hepatitis B virus (HBV) and is not prone to drug-resistance mutations even after 3 years of treatment, according to study results published in the December 22, 2010 advance online edition of Hepatology. Further data presented at a recent liver disease conference indicate that this still remains the case after 4 years.


Experts Devise Roadmap for Development of Direct-acting Hepatitis C Drugs SUMMARY: A group of medical experts, government regulatory officials, pharmaceutical company representatives, and patient advocates met in early December to discuss a promising new approach to hepatitis C treatment and produce a "roadmap" for development and implementation of direct-acting antiviral agents -- including how best to test and use these new drugs in combination regimens, and their use in children. The first agents of this type are expected to be approved in 2011.

Continue reading......


From Medscape


Steady Hep C Mortality Rates Disappoint in Australia

Reuters Health Information, January 4, 2011


HCV -4 Spreads From Egypt and Africa Into Europe

Reuters Health Information, January 4, 2011



Nigeria: What to Know About Hepatitis B

Before blood transfusion is carried out on people, screening tests are done for the presence of certain diseases. Aside the Human immune-deficiency virus (HIV), the second most sought disease is hepatitis B. Some Health Experts say the risk of getting hepatitis from a blood transfusion is currently about 1 in 500,000 for hepatitis B and 1 in 30 million for hepatitis C. The chance of getting HIV or HTLV infection is about 1 in 5 million.


Ligand Licenses Liver Drug Candidates Bruce V. Bigelow

1/6/11 San Diego’s Ligand Pharmaceuticals said today it has licensed two liver drug candidates to Chiva Pharmaceuticals, a Los Altos Hills, CA, affiliate of Hainan Kaihua Pharmaceutical. Ligand says the deal, which gives Chiva rights to develop and market the drugs in China, could be worth more than $100 million in milestone payments and royalties. Ligand also has the potential to get a 10 percent stake in Chiva as well as sublicensing revenue. Ligand acquired drugs a year ago through its acquisition of Metabasis Therapeutics. One drug is a potential treatment for hepatitis B and the other is being tested as a treatment for hepatocellular carcinoma, the most common type of liver cancer.


Liver Cancer

Abnormal Cancer Rates at Fort Detrick Tied to Monsanto's Agent Orange

Tim King Salem-News.com

Monsanto's Agent Orange; the gift of death that keeps on killing... To learn more about Fort Detrick, visit: VeteransToday.com (BALTIMORE, Md.) - Deadly poisons at Fort Detrick in Frederick tied to Agent Orange and the Vietnam War period, have prompted public health officials in Maryland to warn that certain cancers are appearing to occur among younger people who live near the Army Base than in people statewide. Clifford Mitchell of Maryland's Department of Health and Mental Hygiene, told The AP Monday that investigators will probe deeper into the discrepancies involving liver, bone and endocrine cancers. Marked differences in liver cancer have been noted, and health experts in Maryland as well as the EPA, say the matter needs substantial further investigation.


Alnylam presents ALN-VSP phase I liver cancer trial results

Friday, January 07, 2011 16:00 IST Cambridge, MassachusettsAlnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new clinical data from its ALN-VSP phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues. In addition, using a highly precise polymerase chain reaction (PCR)-based technique known as 5'- rapid amplification of cDNA ends (5'-RACE), analysis of human tissue samples showed proof of RNAi-mediated target mRNA cleavage, and thus RNAi in man with the systemically delivered RNAi therapeutic. These results provide significant human proof of concept for Alnylam's efforts in advancing RNAi therapeutics to patients."These data provide conclusive evidence that RNAi can be harnessed in man and, as such, represent a notable and important milestone in the advancement of RNAi therapeutics as a potential new class of medicines," said Phillip Sharp, Ph.D., Institute Professor, The Koch Institute for Integrative Cancer Research, MIT, and Chairman of Alnylam Scientific Advisory Board and Alnylam Director. "I applaud Alnylam scientists, clinicians, and their collaborators for reaching this important achievement and I look forward to the results of their continued efforts."
/

HIV




Does Nevirapine Lower Viral Load More than Efavirenz? SUMMARY: Among the non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs, nevirapine (Viramune) may be able to reduce plasma HIV viral load to a lower level than efavirenz (Sustiva, also in the Truvada and Atripla combination pills), according to a French study described in the December 13, 2010 advance online edition of AIDS. Both drugs suppress virus to undetectable levels using standard tests, but people taking nevirapine were more likely to reach a level below 1 copy/mL.


SUMMARY: A novel type of HIV entry inhibitor dubbed VIR-576, which blocks HIV's ability to insert its gp41 fusion peptide into the outer membrane of a host cell, demonstrated promising safety and efficacy in a small clinical study published in the December 20, 2010 issue of Science Translational Medicine. VIR-576 did not show cross-resistance with other antiretroviral drugs -- including other entry inhibitors -- and is unlikely to promote resistance itself, according to study investigators

Risk Factors for Cancer Mortality among People with HIV SUMMARY: HIV positive people on antiretroviral therapy are more likely to die after cancer diagnosed if they have poor immune function as indicated by a low CD4 T-cell count or are unable to achieve undetectable viral load, according to a study published in the December 14, 2010 advance online edition of AIDS. Regular cancer screening starting at a younger age and prompt treatment could help improve survival in this population, investigators advised.


SUMMARY: The U.S. Food and Drug Administration (FDA) recently approved new dose regimens for 2 widely used antiretroviral drugs. The protease inhibitor darunavir (Prezista), boosted with ritonavir, is now approved for once-daily dosing for treatment-experienced adults with HIV who have no known pre-existing darunavir-associated resistance mutations. The agency also approved a 200 mg formulation of the NNRTI etravirine (Intelence), allowing patients to take fewer pills at a time.


SUMMARY: ViiV Healthcare -- the HIV specialty company formed by GlaxoSmithKline and Pfizer -- announced this week that it will now participate in the Welvista program, a collaborative initiative to provide antiretroviral medications to low-income people on AIDS Drug Assistance Program (ADAP) waiting lists, which are growing in several states in the wake of the ongoing financial crisis.


From NATAP



- (01/07/11)


- (01/07/11)

OraSureTechnologies A Pennsylvania biotech company is currently awaiting FDA approval for the first ever over-the-counter HIV test. In just 20 minutes, the test will reveal whether a person has contracted the virus. No health clinics or hospitals. No agonizing waiting for lab results. Today, the product is only used in medical labs. But OraSure is working with the FDA to gain approval for use in the field by minimally trained staff. An application for over-the-counter sale could be next. Continue reading.... Transplants LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant Patients 07 January 2011LifeCycle Pharma A/S (OMX: LCP) has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro™ tablets administered once-daily versus Prograf® (tacrolimus) capsules...
.


Protect yourself against hepatitis A By DR. DAN BRENNAN -- JAN. 7, 2011 The virus known as hepatitis A has been in the news this week after several hundred parishioners were exposed to the germ at a religious service in New York State. Hepatitis A, often contracted through eating or drinking contaminated food or water, is a vaccine preventable disease often confused with other types of hepatitis viruses.


Healthy You If I Had....... Friday Previously on the blog we posted a weekly video in a series deemed "If I Had." These videos cover numerous disorders and diseases. Physicians share what they would do "IF they Had..." the disease in the topic video.

Today the topic is:


If I Had - A Recurring Cough - Dr. Jennifer Temel, MD



.

Visit Insider Medicine


Hospital Rankings Stumble on Data Reliability
2 hours ago Hospital quality-of-care score cards are only as reliable as the data that go into them, researchers cautioned in a study pointing to substantial statistical "noise" disrupting comparisons in vascular surgery.


FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies


January 2011 09:48 GA_googleFillSlot("NewsMedicalSquares"); Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycemic control across glycosylated hemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG).


Recalled Antibiotic Maker Recalls Underweight Tablets
Teva Pharmaceuticals has issued a recall for a single lot of 250 mg metronidazole tablets because some of the pills may not contain the proper amount of the active ingredient.
.

January 06, 2011



January 05, 2011 -


January 05, 2011 -


Of Interest

Facts Cancer Nanotechnology

December 3, 2010

BY WILLIAM G. GILROY (PhysOrg.com) -- Research directed by Basar Bilgicer, assistant professor of chemical and biomolecular engineering and a member of the Advanced Diagnostics and Therapeutics initiative at the University of Notre Dame, could one day enable clinicians to deliver powerful chemotherapy drugs to tumors without deleterious side effects.


Although chemotherapeutic agents are poisonous to tumors, they also can kill healthy , leading to . Bilgicer’s research involves developing drug- loaded nanoparticles to target the tumor tissue, so that the chemotherapeutic agents can be delivered specifically to the tumors rather than healthy tissue..










Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections

New Expanded Access Study Builds on CMX001 Emergency IND and Clinical Experience Chimerix, Inc. January 7, 2011 8:37am EST


RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2011 — /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

Under the expanded-access protocol developed in conjunction with the U.S. Food and Drug Administration (FDA), patients will receive treatment with CMX001 for any of 12 different dsDNA viral infections, including adenovirus (AdV), herpes viruses (cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein Barr virus), polyoma viruses (BK virus and JC virus), and pox viruses. The CMX001-350 study will enroll 200 patients at major medical centers primarily in the United States.


MX001 is being developed by Chimerix for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients and as a medical countermeasure in the event of a smallpox outbreak. Chimerix is currently conducting a Phase 2 dose-defining clinical study of CMX001 in immunocompromised hematopoietic stem cell transplant patients at risk of life-threatening infection with CMV, which has enrolled over 130 patients. Additionally, the Company is initiating a Phase 2 clinical study in immunocompromised pediatric and adult hematopoietic stem cell transplant patients with AdV infections. "Data from this open-label clinical study will be a critical component of our strategy to develop CMX001 as a broad-spectrum antiviral agent," said Kenneth I. Moch, President and CEO of Chimerix. "We anticipate that the CMX001-350 study will provide important supportive data for our overall clinical development program."


"CMX001 is exhibiting a favorable tolerability profile and signs of potent antiviral activity across our clinical studies, including the more than 130 Emergency INDs requested by leading investigators," said Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix. "The demand for CMX001 to treat life-threatening infections continues to grow among the clinical community, and we are extremely proud to provide CMX001 under this open-label study."


CMX001-350 Open-Label Study Design


he primary objective of the multicenter open-label study of CMX001 is to provide CMX001 to patients with immediately life-threatening or serious disease caused by any of 12 different viral infections resulting from dsDNA viruses. The open-label study is expected to enroll 200 infected adult and pediatric patients. Critically-ill patients expected to enroll in this study in the highest numbers include immunocompromised patients suffering from a variety of dsDNA infections, particularly patients undergoing solid organ transplant or hematopoietic stem cell transplant. However, the study is intended for any patient with a serious dsDNA viral disease for whom no satisfactory alternate therapy is available and who does not qualify for other CMX001 clinical studies.(1)

The study will evaluate the safety, tolerability and antiviral activity of CMX001. Researchers will also evaluate the activity of CMX001 through changes in clinical signs and symptoms of infection. Patients will receive CMX001 orally twice weekly for up to three months, and treatment may be extended for up to six months depending on the patient's clinical response. Antiviral activity will be measured by changes in viral burden from baseline in an individual patient's condition and across all patients with a given dsDNA virus. Drug pharmacokinetics and any potential signs of drug resistance will also be assessed.


The clinical design parameters of the CMX001-350 study were based in large part on Chimerix's experiences providing CMX001 to patients under investigator-held Emergency Investigational New Drug applications (EINDs). At the request of leading physicians, Chimerix has to date provided CMX001 to more than 130 patients under EINDs or foreign equivalent at over 45 medical centers in the United States, Canada, Europe and Israel. CMX001 has been used for the treatment of life-threatening dsDNA infections where either there are no FDA-approved treatments or the patients have failed the available treatments. Patients treated with CMX001 have had infections from all five classes of dsDNA viruses that infect humans, including AdV, herpes viruses such as CMV, HSV and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. Data from these EIND experiences have been recently reported in a number of publications and medical conferences, and are available on the Chimerix website at http://www.chimerix.com/.


Additional information on study objectives, enrollment criteria and patient eligibility for the CMX001-350 study is available at http://www.clinicaltrials.gov/.

About Chimerix Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad-spectrum antiviral agent for the treatment of life-threatening dsDNA viral diseases. Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-305) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. Over 325 people have received CMX001 to date, including over 130 patients treated under Emergency INDs. CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans. CMX001 is also being developed as a medical countermeasure in the event of a smallpox outbreak. Chimerix has received significant funding from the National Institute of Allergy and Infectious Disease to develop CMX001 for smallpox. Chimerix's second clinical-stage antiviral compound CMX157, a potent nucleoside analogue with activity against HIV and hepatitis B, is in development for the treatment of HIV infection including those caused by multi-drug resistant viruses. CMX157 has completed Phase 1 clinical studies demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, suggesting the possibility of a convenient, once-weekly dosing regimen. CMX157's promising safety profile and efficient conversion to the active drug in PBMCs, coupled with the potent in vitro antiviral activity across diverse drug-resistant strains of HIV, indicate that this compound may directly address several limitations of current HIV therapies. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs. For additional information on Chimerix, please visit http://www.chimerix.com/.

(1) Code of Federal Regulations, Title 21, Revised April 2010 SOURCE Chimerix, Inc.



Tuesday, January 4, 2011

Hepatitis News: Investigated Fort Detrick Concern For High Liver Cancer Rates

Fort Detrick cancer cases to be studied
Maryland public health officials say certain cancers appear to occur at younger ages among people living near Fort Detrick in Frederick than in people statewide. Clifford Mitchell of the Department of Health and Mental Hygiene said Monday that...

Hepatocytes derived from induced pluripotent stem cells (iPSCs) could offer an alternative for the future in liver treatment
Today, January 04, 2011, 4 minutes ago
Numerous patients suffering from chronic liver diseases are currently receiving inadequate treatment due to the lack of organs donated for transplantation. However, hepatocytes derived from induced pluripotent stem cells (iPSCs) could offer an alternative for the future. Scientists from the Max Planck Institute for Molecular Genetics in Berlin compared hepatocytes from embryonic stem cells with hepatocytes from iPS cells and found that their gene expression is very similar. Nevertheless, in comparison to "real" hepatocytes, just under half of the genes exhibited a different gene expression. Therefore, the gene expression of hepatocytes derived from iPS cells still requires adaptation before the cells could be used in the treatment of liver diseases.

Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection.
Today, January 04, 2011, 6 hours ago
16 New Abstracts on HCV / Updated Jan 4th 2011
CONCLUSIONS: Several dietary factors and walking may be associated with risk of advanced HCV-related liver disease in male veterans. However, given our modest sample size, our findings must be considered as provisional pending verification in larger prospective studies.
See All Abstracts ...............
.

If I Had.......

Previously on the blog we posted a weekly video in a series deemed "If I Had."

These videos cover numerous disorders and diseases. Physicians share what they would do "IF they Had..." the disease in the topic video.

Today the topic is:
If I Had - Low Platelets With Recent Onset Nosebleeds and Easy Bruising -
.

Dr. David J. Kuter, MD, PhD, Massachusetts General Hospital



The interesting and beneficial series comes to you from Insider Medicine .
Watch For Future If I Had Videos Posted On Fridays

Medscape pubished data today from a study in the December 28, 2010, issue of the World Journal of Gastroenterology on the assoication of Nonalcoholic fatty liver disease (NAFLD) and idiopathic venous thromboembolism(VTE).

What Is VTE ?
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects hospitalized and nonhospitalized patients, recurs frequently, is often overlooked, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS).
Venous thromboembolism results from a combination of hereditary and acquired risk factors, also known as thrombophilia or hypercoagulable states. In addition, vessel wall damage, venous stasis, and increased activation of clotting factors first described by Rudolf Virchow more than a century ago still remain the fundamental basis for our understanding of thrombosis.
Prevalence and risk factors
Venous thromboembolism is the third most common cardiovascular illness after acute coronary syndrome and stroke.1 Although the exact incidence of VTE is unknown, it is believed there are approximately 1 million cases of VTE in the United States each year, many of which represent recurrent disease.2 Nearly two thirds of all VTE events result from hospitalization, and approximately 300, 000 of these patients die.3 Pulmonary embolism is the third most common cause of hospital-related death and it is the most common preventable cause of hospital-related death.4, 5 Most hospitalized patients have at least one or more risk factors for VTE (Box 1). Long-established and well-known cardiovascular risk factors
In case you missed it on the blog

Latest News in Hepatitis C From Medscape

Steady Hep C Mortality Rates Disappoint in Australia
Reuters Health Information, January 4, 2011
HCV -4 Spreads From Egypt and Africa Into Europe
Reuters Health Information, January 4, 2011


I just had to add this folks....




Psychologists have found that George Clooney may be even luckier than previously thought. New research has discovered that as women become more financially independent, they want an older, more ... >





Food For Thought


Released: 1/4/2011 1:20 PM EST
Source: Kansas State University
Newswise — According to recent news reports, the next venue for a terror threat may involve the use of bio-agents to contaminate the food supplies of U.S. hotels and restaurants.
Dave Olds, a December 2010 doctoral graduate in hotel, restaurant, institution management and dietetics from Kansas State University, conducted his dissertation on food security and bioterrorism. His dissertation, "Food Defense Management Practices In Private Country Clubs," examined current safety precautions used by country club restaurants to protect food and beverages, as well as how often those practices were put into effect.
"I identified country clubs because they typically have an exclusive population. They are places often visited by affluent and influential people and their families, and sometimes even government officials," Olds said.

Other national studies on this venue have not been done, Olds said. The idea came from a former K-State study that investigated food bioterrorism in schools and hospitals.
To gather data, Olds, a former chef, surveyed country club managers nationally. In the Midwest he toured the facilities of 25 country clubs and visited with club managers.
"I found that intentional contamination of food isn’t perceived to be a very common occurrence by club managers. In fact, most couldn’t recollect an incident happening," Olds said. "However, it's one of the oldest forms of terrorism, as there are recorded incidents of this happening in Roman history."

Olds found that 21 of the 25 club managers said they didn't think bioterrorism was a risk at their country clubs.

Intentional food contamination can come from two groups: those working inside an operation and those working outside an operation. According to Olds, club managers felt that disgruntled employees were more likely than non-employees to intentionally contaminate food.
An incident of this nature occurred in 2009 at a Kansas City restaurant, rather than a country club, when it was discovered that a former employee had mixed pesticide into salsa, Olds said.
"One of the quotes in a recent news report on food contamination by Al Qaeda in the Arabian Peninsula said that this is a difficult topic to debate without alarming the public. I think that's very true," Olds said. "It's really tricky because you want to educate employees and the board of directors, but you don't want to appear to be causing undo panic or even giving people ideas."
A sidebar with low-cost tips for country club managers can be found at